Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 1168

Matrix Metalloproteinase Inhibitors to Treat Fatty Liver Disease

Inventors: Marsha Moses, Mark Puder

Invention Types: Therapeutics

Research Areas: Internal Medicine, Metabolic Disease

Keywords: Hepactic, New Indication/Use, Obesity, Small Molecule/Drug

For More Information Contact:  Khunkhun, Rajinder

 

Invention Description:

Investigators at Children's Hospital Boston have discovered a novel use of matrix metalloproteinase inhibitors (MMPIs) to treat fatty liver disease. Using a mouse model, they showed that administration of MMPIs prevented the development of fatty liver disease in animals given a diet associated with fat-induced liver damage. Livers of control and experimental animals were evaluated both physically and chemically, and while the animals on the high-fat diet alone developed abnormal liver features, those treated with MMP inhibitors did not. Both the physical features of the liver and chemical liver marker levels in the MMP-treated animals were normal, indicating not only that the MMP inhibitor prevented the development of fat particles in the organ but also protected the cellular function of the hepatocytes.


Fatty liver disease is the precursor to major liver damage, including liver inflammation, scarring, cirrhosis and liver failure. The major causes of fatty liver disease are obesity and diabetes, both of which are on the rise in the United States and elsewhere. The number of people with excessive fat accumulation in the liver is increasing and is estimated to be 30% of the population in both Western European countries and the United States. Up to 10% of this population, 3% of all adults, will develop serious liver disease, including cirrhosis. Last year 60,000 deaths in the United States resulted from liver failure, and there are currently over 17,000 people waiting for a liver transplant.

Applications:

Small molecule treatment for fatty liver disease associated with obesity

Competitive Advantages:

There is currently no treatment for fatty liver disease other than weight loss or liver transplant. This technology has the potential to prevent and treat fatty liver disease, a precursor to liver failure, and thereby reduce liver-related morbidity. This small molecule therapy has the potential to be adopted as the standard of care due to the unmet medical need in this area, representing the potential for a large-market business opportunity.

Business Opportunity:

Exclusive or Non-Exclusive License|Start-up

Key Publications: Inhibition of matrix metalloproteinases increases PPAR-alpha and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model.|Alwayn IP, Andersson C, Lee S, Arsenault DA, Bistrian BR, Gura KM, Nose V, Zauscher B, Moses M, Puder M.|Am J Physiol Gastrointest Liver Physiol. 2006 Dec;291(6):G1011-9.| US Patent Application number 11/997,002

Related Publications: A critical role for matrix metalloproteinases in liver regeneration.|Alwayn IP, Verbesey JE, Kim S, Roy R, Arsenault DA, Greene AK, Novak K, Laforme A, Lee S, Moses MA, Puder M.|J Surg Res. 2008 Apr;145(2):192-8.

IPStatus: Patented